PDGFRA and Mobius syndrome: PDGFRα was initially found to be highly expressed in metastatic MBs, and it was further proposed to be a therapeutic target for metastatic MB based on the results that metastatic MB cells lost their metastatic phenotypes (reduced capabilities on adhesion and migration in vitro) upon blockade of PDGFRα signaling using a PDGFRα-neutralizing antibody and a MAP2K1/2 inhibitor [11, 20].